Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients

NCT03939481 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT03939481
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03939481 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients
Lead sponsor
SWOG Cancer Research Network
Phase
Observational
Overall status
Active, not recruiting
Start date
May 14, 2019
Completion date
February 1, 2027
Enrollment
1,336 (actual)
Sites
169

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage i breast cancer ajcc v8, anatomic stage ia breast cancer ajcc v8, anatomic stage ib breast cancer ajcc v8, anatomic stage ii breast cancer ajcc v8, anatomic stage iia breast cancer ajcc v8, anatomic stage iib breast cancer ajcc v8, anatomic stage iii breast cancer ajcc v8, anatomic stage iiia breast cancer ajcc v8, anatomic stage iiib breast cancer ajcc v8, anatomic stage iiic breast cancer ajcc v8, lung non-small cell carcinoma, prognostic stage i breast cancer ajcc v8, prognostic stage ia breast cancer ajcc v8, prognostic stage ib breast cancer ajcc v8, prognostic stage ii breast cancer ajcc v8, prognostic stage iia breast cancer ajcc v8, prognostic stage iib breast cancer ajcc v8, prognostic stage iii breast cancer ajcc v8, prognostic stage iiia breast cancer ajcc v8, prognostic stage iiib breast cancer ajcc v8, prognostic stage iiic breast cancer ajcc v8, stage i lung cancer ajcc v8, stage i ovarian cancer ajcc v8, stage ia ovarian cancer ajcc v8, stage ia1 lung cancer ajcc v8, stage ia2 lung cancer ajcc v8, stage ia3 lung cancer ajcc v8, stage ib lung cancer ajcc v8, stage ib ovarian cancer ajcc v8, stage ic ovarian cancer ajcc v8, stage ii lung cancer ajcc v8, stage ii ovarian cancer ajcc v8, stage iia lung cancer ajcc v8, stage iia ovarian cancer ajcc v8, stage iib lung cancer ajcc v8, stage iib ovarian cancer ajcc v8, stage iii lung cancer ajcc v8, stage iii ovarian cancer ajcc v8, stage iiia lung cancer ajcc v8, stage iiia ovarian cancer ajcc v8, stage iiia1 ovarian cancer ajcc v8, stage iiia2 ovarian cancer ajcc v8, stage iiib lung cancer ajcc v8, stage iiib ovarian cancer ajcc v8, stage iiic lung cancer ajcc v8, stage iiic ovarian cancer ajcc v8